SNRI sexual side effects: can they last?
Effexor and Cymbalta commonly lower sex drive and delay orgasm. UK leaflets for both warn this has sometimes continued after stopping. That is called PSSD.
SIDEfxHUB is a patient charity. We are not health professionals, and this does not replace medical advice. Don't start, stop or change any medicine because of what you read here. Talk to your doctor first.
If you are in crisis:116 123 Samaritans (UK)988 Lifeline (US)Find a helpline
Effexor (venlafaxine) and Cymbalta (duloxetine) commonly lower sex drive and delay or block orgasm. UK leaflets for both medicines warn this has sometimes continued after stopping, a condition called post-SSRI sexual dysfunction (PSSD).
PSSD is more than a sexual problem. The 2022 diagnostic criteria describe a lasting change in genital sensation, with genitals that can feel numb, and list emotional numbing, problems with thinking and changes in skin, smell, taste or vision too.
Riikka was prescribed Cymbalta for bladder pain, not depression, and took it for seven weeks. After she stopped, her genitals went numb, then painful, then numb again. More than a year later, her desire for sex hadn’t come back.
Her video is under three minutes. Watch it to hear, in her own words, how the numbness began after her last dose.
“Doctor didn’t warn me,” she says. Both medicines are SNRIs, and the name PSSD says SSRI, so it’s easy to think the warning isn’t about you. The NHS pages on venlafaxine and duloxetine list sexual problems, but don’t say they can continue.
The story in 3 lines
- Effexor and Cymbalta commonly lower sex drive, delay orgasm and cause erection problems (Efexor XL leaflet).
- UK leaflets for both warn these problems have sometimes continued after stopping (duloxetine leaflet).
- No reliable figure exists for how often. Patients call it PSSD, a name that covers SNRIs too (diagnostic criteria).
Press: contact@sidefxhub.com
What sexual side effects do Effexor and Cymbalta cause?
Both leaflets list the same problems as common: lower sex drive, trouble reaching orgasm or none at all, erection problems and changes in ejaculation. Duloxetine is also given for anxiety and nerve pain, and for bladder leakage in women as Yentreve. Whatever it’s prescribed for, the leaflet carries the same warning.
Some people notice straight away. Benjamin, who took Cymbalta for a month in 2011, says that after his first capsule “it felt like my genitals were missing”.
When one study asked people directly, about 2 in 3 of those on venlafaxine developed a sexual problem they hadn’t had before. The study had no placebo group to compare with. The researchers wrote that these problems are underestimated unless people are asked with a proper questionnaire.
Can Effexor and Cymbalta sexual side effects last after stopping?
Yes, in some cases. Both leaflets say so, in a sentence that is word for word the same. In 2019 the EU medicines regulator asked for this warning on ten SSRI and SNRI antidepressants, venlafaxine and duloxetine among them.
Efexor XL leaflet: “Sexual problems”
“Medicines like Efexor XL (so called SNRIs) may cause symptoms of sexual dysfunction (see section 4). In some cases, these symptoms have continued after stopping treatment.”
Nobody has measured how often it happens: a review of the research on SSRIs could find no reliable figure. How many people fully get their genital feeling back has “never been properly investigated”, the researchers David Healy and Dee Mangin wrote.
For some people it has lasted years after stopping. Nobody knows yet who will be affected, or whether it will ease.
Benjamin and his twin brother started Cymbalta at the same time and stopped together. His brother’s symptoms lifted. Thirteen years later, Benjamin was still living with PSSD. The interview is long, so start at 3:43 for the part about Cymbalta.
Two other SNRIs, Pristiq (desvenlafaxine) and milnacipran, carry the warning in some countries. The EU’s 2019 wording names both, as do Pristiq’s Canadian product monograph and the French milnacipran information. The US labels for Pristiq and Savella don’t. Neither is licensed in the UK, the MHRA says.
Why is it called post-SSRI if Effexor is an SNRI?
The name says SSRI, but the condition covers SNRIs too. The 2022 criteria, written by an international group of doctors and researchers, require earlier treatment with a “serotonin reuptake inhibitor” and count SNRIs among them. The EU regulator’s own analysis of side-effect reports called PSSD “a misnomer”, a label that doesn’t fit.
An SSRI acts on serotonin, one of the brain’s chemical messengers. An SNRI acts on serotonin and noradrenaline. But one study found that at 75 mg a day, the usual starting dose, venlafaxine acted on serotonin alone, like an SSRI. Only at higher doses did it block noradrenaline too.
This psychiatrist’s talk is background, not evidence about PSSD. It’s worth a look if you want to understand why the dose matters.
What can I do?
These medicines help many people. If you have side effects, that’s a decision for you and your prescriber. Don’t stop suddenly: the Efexor XL leaflet says coming off can take several weeks or months.
Questions to take to your GP
You could open with: “My leaflet says sexual problems can continue after stopping. I think that's happened to me.”
- Could anything else explain these symptoms?
- Can my symptoms and the dates I took the medicine go in my notes?
- Will you report this to the Yellow Card scheme, or should I?
Many people say it took time to be taken seriously. Bring the leaflet line. You can report it without a doctor agreeing.
Report it: it helps everyone
A doctor's note helps you. A report to the medicines regulator helps everyone else: it is how patterns get noticed.
- No proof needed. A suspicion is enough, even years after stopping.
- Where: the Yellow Card scheme in the UK, MedWatch in the US.
- Use the right words. If symptoms continued after stopping, write Post-SSRI sexual dysfunction (MedDRA 10086208). Use it for an SNRI too.
Frequently asked questions
Does Cymbalta cause erectile dysfunction?
It can. The duloxetine leaflet lists problems getting an erection and changes in ejaculation as common side effects. So does the Efexor XL leaflet. If the problem started on the medicine and hasn’t gone since you stopped, that’s what the leaflet’s warning describes. Tell your GP, and report it.
Can sexual problems start after stopping Effexor or Cymbalta?
Yes. The 2022 criteria say the problem “may only appear when the drug is stopped”. Riikka’s numbness began after her last dose. If this happens to you, write down the dates, for example: “Duloxetine 60 mg from January 2023, last capsule March 2024.”
Can Effexor or Cymbalta make you feel emotionally numb?
The Efexor XL leaflet lists “lack of feeling or emotion” as an uncommon side effect. In PSSD, emotional and genital numbing “commonly go together”, the 2022 criteria note, and Riikka says she lost her joy along with her desire. Benjamin’s emotional blunting took five or six years to ease.
Seven weeks of Cymbalta for bladder pain, and more than a year later Riikka was still numb. If something like this has happened to you, report it: that’s how cases like hers get counted.
Sources
- Efexor XL 75 mg, 150 mg and 225 mg prolonged-release capsules, patient information leaflet, last revised October 2025. Electronic Medicines Compendium. Section 2, “Sexual problems”; section 4, common and uncommon side effects; section 3, “If you stop taking Efexor XL”; usual starting dose 75 mg a day.
- Duloxetine 30 mg and 60 mg gastro-resistant capsules, patient information leaflet, last revised August 2024. Electronic Medicines Compendium. Section 2 carries the same sentence on symptoms continuing after stopping; section 4 lists the sexual side effects as common.
- Cymbalta, EPAR product information (summary of product characteristics and package leaflet). European Medicines Agency. The package leaflet, section 2, carries the same sentence.
- Yentreve 20 mg and 40 mg hard gastro-resistant capsules, patient information leaflet, last revised September 2024. Duloxetine for stress urinary incontinence in women; section 2 carries the same sentence.
- NHS, Venlafaxine, last reviewed 6 July 2026, and Duloxetine, last reviewed 18 June 2026. Both list sexual problems such as low sex drive among common side effects; neither mentions problems continuing after stopping.
- European Medicines Agency, PRAC, recommendations on signals adopted at the 13-16 May 2019 meeting, EMA/PRAC/265212/2019, section 1.3. The wording is for ten medicines: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, desvenlafaxine, duloxetine, milnacipran and venlafaxine.
- European Medicines Agency, Serotonin and norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors and other antidepressants and persistent sexual dysfunction: EudraVigilance analysis, EMA/132684/2019, 20 February 2019, section 4.3.1.2.
- Healy D, Bahrick A, Bak M and colleagues. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk Saf Med 2022;33(1):65-76.
- Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry 2001;62 Suppl 3:10-21. Open-label, no placebo group; everyone had normal sexual function before treatment and was asked with a questionnaire. Venlafaxine: 37 of 55 people (67.3%).
- Debonnel G, Saint-André E, Hébert C and colleagues. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol 2007;10(1):51-61. Double-blind study in 44 people with depression; 75 mg against up to 375 mg a day.
- Tarchi L, Merola GP, Baccaredda-Boy O and colleagues. Selective serotonin reuptake inhibitors, post-treatment sexual dysfunction and persistent genital arousal disorder: a systematic review. Pharmacoepidemiol Drug Saf 2023;32(10):1053-67.
- Healy D, Mangin D. Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence. Epidemiol Psychiatr Sci 2024;33:e40.
- Pristiq (desvenlafaxine) extended-release tablets 50 mg and 100 mg, product monograph, Pfizer Canada ULC, date of revision 12 February 2024. Health Canada, Drug Product Database. Section 7, Reproductive Health: Female and Male Potential, Function.
- Pristiq (desvenlafaxine) extended-release tablets, prescribing information, revised June 2025. DailyMed. Section 5.11, Sexual Dysfunction; no sentence about symptoms continuing after stopping.
- MHRA, Antidepressants: use and safety, updated 15 October 2026. Section 3, footnote 2: desvenlafaxine and milnacipran are not licensed in the UK.
- Milnacipran Arrow 25 mg capsules, résumé des caractéristiques du produit, Arrow Génériques, updated in the database 14 December 2021. Base de données publique des médicaments (France). Section 4.4, Dysfonction sexuelle.
- Savella (milnacipran HCl) tablets, prescribing information, revised September 2025. DailyMed. For fibromyalgia; section 5.12, Sexual Dysfunction; no sentence about symptoms continuing after stopping.
- Videos: PSSD Network, Riikka’s story (29 June 2023); Moral Medicine, interview with Benjamin (16 July 2024), also on our site as Benjamin’s story; Dr Sanil Rege, The difference between venlafaxine and desvenlafaxine (13 March 2022).
This information does not replace medical advice. Talk to your doctor before you make any decision about your treatment.
640+ people have joined the registry.
Join them, then report your side effects.
Free. Sign up takes 2 minutes.
Venlafaxine: what the official texts say, country by country
For the SNRI antidepressant venlafaxine (Effexor XR, Efexor XL), the product information we read in the United Kingdom and in Canada says there have been reports of long-lasting sexual dysfunction where symptoms continued after SNRIs were stopped. This is known as post-SSRI sexual dysfunction (PSSD). The EU medicines regulator set the wording of this warning in 2019 for ten medicines, venlafaxine among them. In the United States, the Effexor XR text for professionals has no such sentence.
This is a record of what each text says and of the date it prints. A text is quoted in its own words, or summarised where the row says so. It is not a comparison of countries. All medicines and countries
Venlafaxine: the official texts, country by country (31 texts read)
| Country or region | What the text says | Document | Dates |
|---|---|---|---|
| United Kingdom | Sexual side effects that continue after stopping4.4 Special warnings and precautions for use · Sexual dysfunction Sexual side effects, as listed4.8 Undesirable effects · Psychiatric disorders · Common Sexual side effects, as listed4.8 Undesirable effects · Psychiatric disorders · Uncommon Sexual side effects, as listed4.8 Undesirable effects · Reproductive system and breast disorders · Common A table cell or list line is shown whole, as the text prints it. Some of them also name side effects that are not sexual. | Text for professionals Summary of Product Characteristics (SmPC): Efexor XL 150 mg prolonged-release capsules, hardEfexor XL prolonged-release capsules, hard, Viatris Products Limited · Read in a compendium of product information: emcAlso on record: patients' leaflet, with such a sentence; 2 related documents, with such a sentence | Text revisedChecked |
| European Union | Sexual side effects that continue after stopping3. Serotonin and noradrenaline reuptake inhibitors (SNRI); selective serotonin reuptake inhibitors (SSRI) – Persistent sexual dysfunction after drug withdrawal (EPITT no 19277) · Summary of product characteristics · 4.4. Special warnings and precautions for use · Sexual dysfunction Sexual side effects that continue after stopping3. Serotonin and noradrenaline reuptake inhibitors (SNRI); selective serotonin reuptake inhibitors (SSRI) – Persistent sexual dysfunction after drug withdrawal (EPITT no 19277) · Package leaflet · 2. What you need to know before you take [Invented name] · Warnings and precautions The wording is for ten medicines: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, desvenlafaxine, duloxetine, milnacipran and venlafaxine. This is wording for national product texts. There is no single EU product text for this medicine. | Document from the regulator New product information wording – Extracts from PRAC recommendations on signals. Adopted at the 13-16 May 2019 PRACRead on the regulator's site: European Medicines AgencyAlso on record: 1 more related document, with such a sentence | PublishedChecked |
| United States | Sexual side effects, as listed5 WARNINGS AND PRECAUTIONS · 5.13 Sexual Dysfunction This text has no sentence about sexual side effects continuing after the medicine is stopped. This text names sexual side effects in several places that this row does not show. Together those passages are too long to reproduce here. The document link in this row opens the text. That they are not shown says nothing about how common these side effects are. On 20 October 2026 we searched the labels in openFDA, the FDA's open database. A sentence about sexual dysfunction continuing after stopping stood on none of the 503 labels in that database that name venlafaxine. | Text for professionals EFFEXOR XR® (venlafaxine extended-release) capsules, for oral use: Full Prescribing InformationEffexor XR extended-release capsules 37.5 mg, 75 mg and 150 mg, Viatris Specialty LLC · Read in the government's medicines database: DailyMedAlso on record: patients' leaflet, with no such sentence | Text revisedChecked |
| Canada | Sexual side effects that continue after stopping7 WARNINGS AND PRECAUTIONS · Reproductive Health: Female and Male Potential · Function This text names sexual side effects in several places that this row does not show. Together those passages are too long to reproduce here. The document link in this row opens the text. That they are not shown says nothing about how common these side effects are. | Text for professionals PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION: EFFEXOR XR, Venlafaxine Hydrochloride Extended Release CapsulesEffexor XR extended release capsules 37.5 mg, 75 mg and 150 mg venlafaxine, BGP Pharma ULC · Read in the regulator's own database: Drug Product DatabaseAlso on record: patients' leaflet, with such a sentence; 2 related documents, with such a sentence | Text revisedChecked |
| Australia | Sexual side effects that continue after stoppingSection 4.4 · Sexual DysfunctionSection 4.4 of Australia's product information for Efexor-XR has a warning headed sexual dysfunction. It says there are reports of sexual dysfunction that lasted a long time, with symptoms going on after SNRIs were stopped.Summarised, not quoted, because of the TGA's access terms. The regulator's site asks readers to accept its terms before it shows this text. | Text for professionals AUSTRALIAN PRODUCT INFORMATION – EFEXOR®-XR (venlafaxine hydrochloride) modified release capsuleEFEXOR-XR, Viatris Pty Ltd · Read in the regulator's own database: TGA eBSAlso on record: patients' leaflet, with such a sentence | Text revisedChecked |
| New Zealand | Sexual side effects that continue after stopping4.4 Special warnings and precautions for use · Sexual Dysfunction Sexual side effects, as listed4.8 Undesirable effects · Psychiatric Disorders · Common: Sexual side effects, as listed4.8 Undesirable effects · Psychiatric Disorders · Uncommon: Sexual side effects, as listed4.8 Undesirable effects · Reproductive System and Breast Disorders · Common: Texts for other products in this country do not all say the same. The ones we read are on the full record. A table cell or list line is shown whole, as the text prints it. Some of them also name side effects that are not sexual. | Text for professionals New Zealand Data Sheet, Efexor-XREfexor-XR modified release capsules, Viatris Ltd · Read in the regulator's own database: MedsafeAlso on record: 1 more text for professionals, with such a sentence; 2 patients' leaflets, with such a sentence; related document, with such a sentence | Text revisedChecked |
| Germany | Sexual side effects that continue after stopping4.4 Besondere Warnhinweise und Vorsichtsmaßnahmen für die Anwendung · Sexuelle Funktionsstörung Sexual side effects, as listed4.8 Nebenwirkungen · Psychiatrische Erkrankungen · Häufig Sexual side effects, as listed4.8 Nebenwirkungen · Psychiatrische Erkrankungen · Gelegentlich Sexual side effects, as listed4.8 Nebenwirkungen · Erkrankungen der Geschlechtsorgane und der Brustdrüse · Häufig This is the copy in a compendium of product information. The regulator's database asks visitors to accept its terms first, which we did not do. A table cell or list line is shown whole, as the text prints it. Some of them also name side effects that are not sexual. | Text for professionals FachinformationTrevilor® retard Hartkapseln, retardiert, Viatris Pharma GmbH · Read in a compendium of product information: fachinfo.deAlso on record: patients' leaflet, with such a sentence; related document, with such a sentence | Text revisedChecked |
| France | Sexual side effects that continue after stopping4.4. Mises en garde spéciales et précautions d'emploi · Dysfonction sexuelle Sexual side effects, as listed4.8. Effets indésirables · Affections psychiatriques · Fréquent Sexual side effects, as listed4.8. Effets indésirables · Affections psychiatriques · Peu fréquent Sexual side effects, as listed4.8. Effets indésirables · Affections des organes de reproduction et du sein · Fréquent The text itself prints no date of revision. Texts for other products in this country do not all say the same. We searched them for sentences about sexual side effects continuing after stopping and did not read them whole. This row shows the product named, and no other. A table cell or list line is shown whole, as the text prints it. Some of them also name side effects that are not sexual. | Text for professionals Résumé des Caractéristiques du ProduitEFFEXOR L.P. 37,5 mg, gélule à libération prolongée, VIATRIS UP · Read in the government's medicines database: Base de données publique des médicamentsAlso on record: patients' leaflet, with such a sentence | Updated by the regulatorChecked |
| Italy | Sexual side effects that continue after stopping4.4 Avvertenze speciali e precauzioni di impiego · Disfunzione sessuale Sexual side effects, as listed4.8 Effetti indesiderati · Disturbi psichiatrici · Comune Sexual side effects, as listed4.8 Effetti indesiderati · Disturbi psichiatrici · Non comune Sexual side effects, as listed4.8 Effetti indesiderati · Patologie dell'apparato riproduttivo e della mammella · Comune The text itself prints no date of revision. A table cell or list line is shown whole, as the text prints it. Some of them also name side effects that are not sexual. | Text for professionals Riassunto delle caratteristiche del prodottoEfexor capsule rigide a rilascio prolungato, Viatris Pharma S.r.l. · Read in the regulator's own database: Banca Dati FarmaciAlso on record: patients' leaflet, with such a sentence | Made available by the regulatorChecked |
| Spain | Sexual side effects that continue after stopping4.4. Advertencias y precauciones especiales de empleo · Disfunción sexual Sexual side effects, as listed4.8. Reacciones adversas · Trastornos psiquiátricos · Frecuentes Sexual side effects, as listed4.8. Reacciones adversas · Trastornos psiquiátricos · Poco frecuentes Sexual side effects, as listed4.8. Reacciones adversas · Trastornos del aparato reproductor y de la mama · Frecuentes A table cell or list line is shown whole, as the text prints it. Some of them also name side effects that are not sexual. | Text for professionals Ficha técnicaVandral Retard cápsulas duras de liberación prolongada, Viatris Healthcare Limited · Read in the regulator's own database: CIMAAlso on record: patients' leaflet, with such a sentence; related document, with such a sentence | Text revisedChecked |
| Brazil | Sexual side effects that continue after stopping5. ADVERTÊNCIAS E PRECAUÇÕES · Disfunção Sexual Sexual side effects, as listed9. REAÇÕES ADVERSAS · Distúrbios psiquiátricos · Comum ≥ 1/100 a <1/10 Sexual side effects, as listed9. REAÇÕES ADVERSAS · Distúrbios psiquiátricos · Incomum ≥ 1/1.000 a <1/100 Sexual side effects, as listed9. REAÇÕES ADVERSAS · Distúrbios do Sistema reprodutivo e mama · Comum ≥ 1/100 a <1/10 This is the holder's own copy. The regulator's database refused our requests (it blocks by country; we asked from Denmark). A table cell or list line is shown whole, as the text prints it. Some of them also name side effects that are not sexual. | Text for professionals EFEXOR XR cloridrato de venlafaxina: bula para o profissional de saúdeEfexor XR cápsulas duras de liberação prolongada 37,5 mg, 75 mg e 150 mg, Viatris Farmacêutica do Brasil Ltda. · Read on the holder's own site: Viatris Farmacêutica do Brasil Ltda.Also on record: patients' leaflet, with such a sentence | Text approvedChecked |
| India | We could not open this text on 20 October 2026: this regulator publishes no database of such texts. This says nothing about what the text contains. | Text for professionalsWe tried: cdsco.gov.in/opencms/opencms/en/Notifications/Prescribing-Information/ | Tried |
Brand names
These are the brand names of venlafaxine we saw in the official lists, compendia and regulators' pages we opened on or after 20 October 2026. A country may have more.
- Effexor XR
- United States, Canada
- Efexor XL
- United Kingdom
- Efexor
- Italy, Brazil
- Efexor-XR
- New Zealand
- Effexor L.P.
- France
- Trevilor retard
- Germany
- Vandral Retard
- Spain
- Sunveniz XL
- United Kingdom
- Venaxx XL
- United Kingdom
- Vencarm XL
- United Kingdom
- Venladex XL
- United Kingdom
- Venlasov XL
- United Kingdom
- Vensir XL
- United Kingdom
- Venzip XL
- United Kingdom
- ViePax XL
- United Kingdom
- Enlafax XR
- New Zealand
- Zarelis
- Italy
- Ixilania
- Italy
- Zaredrop
- Italy
- Dislaven Retard
- Spain
- Dobupal Retard
- Spain
- Dobupal
- Spain
- Venlabrain Retard
- Spain
- Venlapine Retard
- Spain
- Zarelis Retard
- Spain
- Alenthus Xr
- Brazil
- Altven
- Brazil
- Venf Xr
- Brazil
- Venforin
- Brazil
- Veniz Xr
- Brazil
- Venlaxin Xr
- Brazil
- Venlift Od
- Brazil
- Vensate Lp
- Brazil
What is not known
- No reliable figure exists for how often PSSD happens. (source)
- One study of health records gives an estimate for men, counted through prescriptions for erection medicines. (source)
- It is not known how many people fully recover. (source)
- None of the product texts we read says how long the sexual dysfunction can last. (source)
Code and reporting
In a report to a medicines regulator, the term is Post-SSRI sexual dysfunction (MedDRA code 10086208). Where to report, country by country
Every row in this table was checked on or after . To quote this record, name SIDEfxHUB and give this page's address. All medicines and countries · The whole record as a file: JSON · CSV · How these texts are checked
You may reuse this record under CC BY 4.0 if you credit SIDEfxHUB and give this page's address. The licence covers our compilation, not the texts quoted in it, in the original or in our translation, and not the article above.
Duloxetine: what the official texts say, country by country
For the SNRI antidepressant duloxetine (Cymbalta), the product information we read in the United Kingdom, that of a generic product, and in the European Union, that of Cymbalta, says there have been reports of long-lasting sexual dysfunction where symptoms continued after SSRIs or SNRIs were stopped. This is known as post-SSRI sexual dysfunction (PSSD). The EU medicines regulator set the wording of this warning in 2019 for ten medicines, duloxetine among them. In Canada, the texts for professionals of some duloxetine products have such a sentence and others do not. In the United States, the last Cymbalta text for professionals has no such sentence.
This is a record of what each text says and of the date it prints. A text is quoted in its own words, or summarised where the row says so. It is not a comparison of countries. All medicines and countries
Duloxetine: the official texts, country by country (31 texts read)
| Country or region | What the text says | Document | Dates |
|---|---|---|---|
| United Kingdom | Sexual side effects that continue after stopping4.4 Special warnings and precautions for use · Sexual dysfunction Sexual side effects, as listed4.8 Undesirable effects · Psychiatric disorders · Common Sexual side effects, as listed4.8 Undesirable effects · Reproductive system and breast disorders · Common Sexual side effects, as listed4.8 Undesirable effects · Reproductive system and breast disorders · Uncommon The same text also says4.8 Undesirable effects · Summary of the safety profile The originator product is not in the list we read. This is another product from that list. A table cell or list line is shown whole, as the text prints it. Some of them also name side effects that are not sexual. | Text for professionals Summary of Product Characteristics (SmPC): Duloxetine Zentiva 30 mg gastro-resistant hard capsulesDuloxetine Zentiva 30 mg gastro-resistant hard capsules, Zentiva Pharma UK Limited · Read in a compendium of product information: emcAlso on record: patients' leaflet, with such a sentence; 2 related documents, with such a sentence | Text revisedChecked |
| European Union | Sexual side effects that continue after stopping4.4 Special warnings and precautions for use · Sexual dysfunction Sexual side effects, as listed4.8 Undesirable effects · Psychiatric disorders · Common Sexual side effects, as listed4.8 Undesirable effects · Reproductive system and breast disorders · Common Sexual side effects, as listed4.8 Undesirable effects · Reproductive system and breast disorders · Uncommon The same text also says4.8 Undesirable effects The text itself prints no date of revision. A table cell or list line is shown whole, as the text prints it. Some of them also name side effects that are not sexual. | Text for professionals ANNEX I SUMMARY OF PRODUCT CHARACTERISTICSCymbalta 30 mg and 60 mg hard gastro-resistant capsules, Eli Lilly Nederland B.V. · Read on the regulator's site: European Medicines AgencyAlso on record: patients' leaflet, with such a sentence; 2 related documents, with such a sentence | The text prints no dateChecked |
| United States | Sexual side effects, as listed5 WARNINGS AND PRECAUTIONS · 5.16 Sexual Dysfunction The same text also says5 WARNINGS AND PRECAUTIONS · 5.16 Sexual Dysfunction This text has no sentence about sexual side effects continuing after the medicine is stopped. An official list of medicines we read shows this product as discontinued or no longer marketed, and the text in this row is still this product's own. This text names sexual side effects in several places that this row does not show. Together those passages are too long to reproduce here. The document link in this row opens the text. That they are not shown says nothing about how common these side effects are. On 20 October 2026 we searched the labels in openFDA, the FDA's open database. A sentence about sexual dysfunction continuing after stopping stood on none of the 319 labels in that database that name duloxetine. | Text for professionals CYMBALTA (duloxetine delayed-release capsules), for oral use: Full Prescribing InformationCymbalta delayed-release capsules 20 mg, 30 mg and 60 mg, Eli Lilly and Company · Read in the government's medicines database: DailyMedAlso on record: patients' leaflet, with no such sentence | Text revisedChecked |
| Canada | This text has no sentence about sexual side effects continuing after the medicine is stopped. An official list of medicines we read shows the originator product as cancelled, revoked or archived. This is the text of another product, the one named in this row. Texts for other products in this country do not all say the same. The ones we read are on the full record. On 20 October 2026 we searched the 19 product monographs of the duloxetine products marked as marketed in Health Canada's database. Of these, 10 had the sentence about sexual dysfunction continuing after stopping in their warnings section, and 9 did not, the one in this row among them. None had it in the part for patients. This text names sexual side effects in several places that this row does not show. Together those passages are too long to reproduce here. The document link in this row opens the text. That they are not shown says nothing about how common these side effects are. | Text for professionals PRODUCT MONOGRAPH: ACCEL-DULOXETINE (Duloxetine Delayed-Release Capsules)ACCEL-DULOXETINE delayed-release capsules 30 mg and 60 mg, Accel Pharma Inc. · Read in the regulator's own database: Drug Product DatabaseAlso on record: 1 more text for professionals, with such a sentence; 2 patients' leaflets, with no such sentence; 2 related documents, with such a sentence | Text revisedChecked |
| Australia | Sexual side effects that continue after stoppingSection 4.4 · Sexual DysfunctionSection 4.4 of Australia's product information for APO-Duloxetine has a warning headed sexual dysfunction. It says there are reports of sexual dysfunction that lasted a long time, with symptoms going on after SSRIs or SNRIs were stopped.Summarised, not quoted, because of the TGA's access terms.In this product's text since 2024, according to the text for professionals, 5 July 2024. The regulator's site asks readers to accept its terms before it shows this text. The originator product is not in the list we read. This is another product from that list. | Text for professionals APO-DULOXETINE (DULOXETINE HYDROCHLORIDE) ENTERIC CAPSULESAPO-DULOXETINE, Arrotex Pharmaceuticals Pty Ltd · Read in the regulator's own database: TGA eBSAlso on record: patients' leaflet, with no such sentence | Text revisedChecked |
| New Zealand | We could not open this text on 20 October 2026: the site did not answer. This says nothing about what the text contains. | Text for professionalsWe tried: www.medsafe.govt.nz/DbSearch/ | Tried |
| Germany | Sexual side effects that continue after stopping4.4 Besondere Warnhinweise und Vorsichtsmaßnahmen für die Anwendung · Sexuelle Funktionsstörung Sexual side effects, as listed4.8 Nebenwirkungen · Psychiatrische Erkrankungen · Häufig Sexual side effects, as listed4.8 Nebenwirkungen · Erkrankungen der Geschlechtsorgane und der Brustdrüse · Häufig Sexual side effects, as listed4.8 Nebenwirkungen · Erkrankungen der Geschlechtsorgane und der Brustdrüse · Gelegentlich The same text also says4.8 Nebenwirkungen · Zusammenfassung des Nebenwirkungsprofils The originator product is not in the list we read. This is another product from that list. This is the holder's own copy. The regulator's database asks visitors to accept its terms first, which we did not do. A table cell or list line is shown whole, as the text prints it. Some of them also name side effects that are not sexual. | Text for professionals FachinformationDuloxetin-ratiopharm® 30 mg und 60 mg magensaftresistente Hartkapseln, ratiopharm GmbH · Read on the holder's own site: ratiopharm GmbHAlso on record: 1 more text for professionals, could not be opened; patients' leaflet, with such a sentence; patients' leaflet, could not be opened; related document, with such a sentence | Text revisedChecked |
| France | Sexual side effects that continue after stopping4.4 Mises en garde spéciales et précautions d’emploi · Dysfonction sexuelle Sexual side effects, as listed4.8 Effets indésirables · Affections psychiatriques · Fréquent Sexual side effects, as listed4.8 Effets indésirables · Affections des organes de reproduction et du sein · Fréquent Sexual side effects, as listed4.8 Effets indésirables · Affections des organes de reproduction et du sein · Peu fréquent The same text also says4.8 Effets indésirables · a. Résumé du profil de sécurité The text itself prints no date of revision. An official list of medicines we read shows this product as discontinued or no longer marketed, and the text in this row is still this product's own. Texts for other products in this country do not all say the same. We searched them for sentences about sexual side effects continuing after stopping and did not read them whole. This row shows the product named, and no other. A table cell or list line is shown whole, as the text prints it. Some of them also name side effects that are not sexual. | Text for professionals Résumé des Caractéristiques du Produit (RCP)CYMBALTA gélule gastro-résistante, ELI LILLY NEDERLAND BV · Read in the government's medicines database: Base de données publique des médicamentsAlso on record: 1 more text for professionals, with such a sentence; 2 patients' leaflets, with such a sentence | The text prints no dateChecked |
| Italy | Sexual side effects that continue after stopping4.4 Avvertenze speciali e precauzioni di impiego · Disfunzione sessuale Sexual side effects, as listed4.8 Effetti indesiderati · Disturbi psichiatrici · Comune Sexual side effects, as listed4.8 Effetti indesiderati · Patologie dell'apparato riproduttivo e della mammella · Comune Sexual side effects, as listed4.8 Effetti indesiderati · Patologie dell'apparato riproduttivo e della mammella · Non comune The same text also says4.8 Effetti indesiderati · a. Sommario del profilo di sicurezza The text itself prints no date of revision. A table cell or list line is shown whole, as the text prints it. Some of them also name side effects that are not sexual. | Text for professionals Riassunto delle caratteristiche del prodottoCymbalta 30 mg e 60 mg capsule rigide gastroresistenti, Eli Lilly Nederland B.V. · Read in the regulator's own database: Banca Dati FarmaciAlso on record: patients' leaflet, with such a sentence | Made available by the regulatorChecked |
| Spain | Sexual side effects that continue after stopping4.4 Advertencias y precauciones especiales de empleo · Disfunción sexual Sexual side effects, as listed4.8 Reacciones adversas · Trastornos psiquiátricos · Frecuentes Sexual side effects, as listed4.8 Reacciones adversas · Trastornos del aparato reproductor y de la mama · Frecuentes Sexual side effects, as listed4.8 Reacciones adversas · Trastornos del aparato reproductor y de la mama · Poco frecuentes The same text also says4.8 Reacciones adversas · Resumen del perfil de seguridad The text itself prints no date of revision. A table cell or list line is shown whole, as the text prints it. Some of them also name side effects that are not sexual. | Text for professionals Ficha técnicaCymbalta 30 mg y 60 mg cápsulas duras gastrorresistentes, Eli Lilly Nederland B.V. · Read in the regulator's own database: CIMAAlso on record: patients' leaflet, with such a sentence; related document, with such a sentence | The text prints no dateChecked |
| Brazil | We could not open this text on 20 October 2026: the holder publishes no text; the site refused our requests (it blocks by country; we asked from Denmark). This says nothing about what the text contains. | Patient leafletDullo, Sun Farmacêutica do Brasil Ltda.We tried: www.sunpharma.com/brazilAlso on record: text for professionals, could not be opened; 1 more patients' leaflet, with no such sentence; 1 more patients' leaflet, could not be opened | Tried |
| India | We could not open this text on 20 October 2026: this regulator publishes no database of such texts. This says nothing about what the text contains. | Text for professionalsWe tried: cdsco.gov.in/opencms/opencms/en/Notifications/Prescribing-Information/ | Tried |
Brand names
These are the brand names of duloxetine we saw in the official lists, compendia and regulators' pages we opened on or after 20 October 2026. A country may have more.
- Cymbalta
- United States, France, Italy, Spain
- Drizalma Sprinkle
- United States
- Yentreve
- United Kingdom, Italy, Spain
- Ezequa
- Italy
- Siloxezol
- Italy
- Dulex
- Italy
- Alikres
- Italy
- Dulxetenon
- Italy
- Oxitril
- Spain
- Dedulox
- Spain
- Dulotex
- Spain
- Ludotim
- Spain
- Xeristar
- Spain
- Cymbi
- Brazil
- Dep
- Brazil
- Deprasil
- Brazil
- Dual
- Brazil
- Duatlo
- Brazil
- Dullo
- Brazil
- Duxxen
- Brazil
- Leduo
- Brazil
- Mydulo
- Brazil
- Neulox
- Brazil
- Sozz
- Brazil
- Sympta
- Brazil
- Velija
- Brazil
What is not known
- No reliable figure exists for how often PSSD happens. (source)
- One study of health records gives an estimate for men, counted through prescriptions for erection medicines. (source)
- It is not known how many people fully recover. (source)
- None of the product texts we read says how long the sexual dysfunction can last. (source)
Code and reporting
In a report to a medicines regulator, the term is Post-SSRI sexual dysfunction (MedDRA code 10086208). Where to report, country by country
Every row in this table was checked on or after . To quote this record, name SIDEfxHUB and give this page's address. All medicines and countries · The whole record as a file: JSON · CSV · How these texts are checked
You may reuse this record under CC BY 4.0 if you credit SIDEfxHUB and give this page's address. The licence covers our compilation, not the texts quoted in it, in the original or in our translation, and not the article above.
Desvenlafaxine: what the official texts say, country by country
For the SNRI antidepressant desvenlafaxine (Pristiq), the product information we read in Canada says there have been reports of long-lasting sexual dysfunction where symptoms continued after SNRIs were stopped. This is known as post-SSRI sexual dysfunction (PSSD). The EU medicines regulator set the wording of this warning in 2019 for ten medicines, desvenlafaxine among them. In the United States, the Pristiq text for professionals has no such sentence.
This is a record of what each text says and of the date it prints. A text is quoted in its own words, or summarised where the row says so. It is not a comparison of countries. All medicines and countries
Desvenlafaxine: the official texts, country by country (19 texts read)
| Country or region | What the text says | Document | Dates |
|---|---|---|---|
| United Kingdom | We found no product with this medicine on 20 October 2026. | Text for professionalsWhere we looked: www.gov.uk/government/publications/antidepressants-use-and-safety--2/selective-serotonin-reuptake-inhibitors-ssris-and-serotonin-and-noradrenaline-reuptake-inhibitors-snris-use-and-safety | Checked |
| European Union | Sexual side effects that continue after stopping3. Serotonin and noradrenaline reuptake inhibitors (SNRI); selective serotonin reuptake inhibitors (SSRI) – Persistent sexual dysfunction after drug withdrawal (EPITT no 19277) · Summary of product characteristics · 4.4. Special warnings and precautions for use · Sexual dysfunction Sexual side effects that continue after stopping3. Serotonin and noradrenaline reuptake inhibitors (SNRI); selective serotonin reuptake inhibitors (SSRI) – Persistent sexual dysfunction after drug withdrawal (EPITT no 19277) · Package leaflet · 2. What you need to know before you take [Invented name] · Warnings and precautions The wording is for ten medicines: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, desvenlafaxine, duloxetine, milnacipran and venlafaxine. This is wording for national product texts. There is no single EU product text for this medicine. | Document from the regulator New product information wording – Extracts from PRAC recommendations on signals. Adopted at the 13-16 May 2019 PRACRead on the regulator's site: European Medicines AgencyAlso on record: 1 more related document, with such a sentence | PublishedChecked |
| United States | Sexual side effects, as listed5 WARNINGS AND PRECAUTIONS · 5.11 Sexual Dysfunction The same text also says5 WARNINGS AND PRECAUTIONS · 5.11 Sexual Dysfunction This text has no sentence about sexual side effects continuing after the medicine is stopped. This text names sexual side effects in several places that this row does not show. Together those passages are too long to reproduce here. The document link in this row opens the text. That they are not shown says nothing about how common these side effects are. On 20 October 2026 we searched the labels in openFDA, the FDA's open database. A sentence about sexual dysfunction continuing after stopping stood on none of the 75 labels in that database that name desvenlafaxine. | Text for professionals PRISTIQ® (desvenlafaxine) Extended-Release Tablets, for oral use: Full Prescribing InformationPristiq extended-release tablets 25 mg, 50 mg and 100 mg, Wyeth Pharmaceuticals LLC · Read in the government's medicines database: DailyMedAlso on record: patients' leaflet, with no such sentence | Text revisedChecked |
| Canada | Sexual side effects that continue after stopping7 WARNINGS AND PRECAUTIONS · Reproductive Health: Female and Male Potential · Function This text names sexual side effects in several places that this row does not show. Together those passages are too long to reproduce here. The document link in this row opens the text. That they are not shown says nothing about how common these side effects are. | Text for professionals PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION: PRISTIQ®, desvenlafaxine extended-release tabletsPristiq extended-release tablets 50 mg and 100 mg desvenlafaxine, Pfizer Canada ULC · Read in the regulator's own database: Drug Product DatabaseAlso on record: patients' leaflet, with such a sentence; 2 related documents, with such a sentence | Text revisedChecked |
| Australia | Sexual side effects that continue after stoppingSection 4.4 · Sexual DysfunctionSection 4.4 of Australia's product information for Pristiq has a warning headed sexual dysfunction. It says there are reports of sexual dysfunction that lasted a long time, with symptoms going on after SNRIs were stopped.Summarised, not quoted, because of the TGA's access terms. The regulator's site asks readers to accept its terms before it shows this text. | Text for professionals AUSTRALIAN PRODUCT INFORMATION – PRISTIQ DESVENLAFAXINE (as SUCCINATE) TABLETSPRISTIQ, Pfizer Australia Pty Ltd · Read in the regulator's own database: TGA eBSAlso on record: patients' leaflet, with no such sentence | Text revisedChecked |
| New Zealand | We could not open this text on 20 October 2026: the site did not answer. This says nothing about what the text contains. | Text for professionalsWe tried: www.medsafe.govt.nz/DbSearch/ | Tried |
| Germany | Sexual side effects that continue after stoppingPRAC-Meldungen · Neufassung des Wortlauts der Produktinformationen – Auszüge aus den Empfehlungen des PRAC zu Signalen · Serotonin- und Noradrenalin-Wiederaufnahmehemmer (SNRI); selektive Serotonin-Wiederaufnahmehemmer (SSRI) – persistierende sexuelle Funktionsstörung nach Absetzen von Arzneimitteln (EPITT Nr. 19277) The wording is for ten medicines: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, desvenlafaxine, duloxetine, milnacipran and venlafaxine. | Document from the regulator Bulletin zur Arzneimittelsicherheit – Informationen aus BfArM und PEI, Ausgabe 2 | Juni 2019Read on the regulator's site: BfArMAlso on record: text for professionals, could not be opened | PublishedChecked |
| France | We found no product with this medicine on 20 October 2026. | Text for professionalsWhere we looked: base-donnees-publique.medicaments.gouv.fr/ | Checked |
| Italy | Sexual side effects that continue after stopping4.4 Avvertenze speciali e precauzioni d’ impiego · Disfunzione sessuale Sexual side effects, as listed4.8 Effetti indesiderati · Disturbi psichiatrici · Comune Sexual side effects, as listed4.8 Effetti indesiderati · Disturbi psichiatrici · Non comune Sexual side effects, as listed4.8 Effetti indesiderati · Patologie dell'apparato riproduttivo e della mammella · Comune Sexual side effects, as listed4.8 Effetti indesiderati · Patologie dell'apparato riproduttivo e della mammella · Non comune The same text also says4.8 Effetti indesiderati The text itself prints no date of revision. The originator product is not in the list we read. This is another product from that list. A table cell or list line is shown whole, as the text prints it. Some of them also name side effects that are not sexual. | Text for professionals Riassunto delle caratteristiche del prodottoFaxilex 50 mg e 100 mg compresse a rilascio prolungato, Neuraxpharm Italy S.p.A. · Read in the regulator's own database: Banca Dati FarmaciAlso on record: patients' leaflet, with such a sentence | Made available by the regulatorChecked |
| Spain | Sexual side effects that continue after stopping4.4. Advertencias y precauciones especiales de empleo · Disfunción sexual Sexual side effects, as listed4.8. Reacciones adversas · Trastornos psiquiátricos · Frecuentes Sexual side effects, as listed4.8. Reacciones adversas · Trastornos psiquiátricos · Poco frecuentes Sexual side effects, as listed4.8. Reacciones adversas · Trastornos del aparato reproductor y de la mama · Frecuentes Sexual side effects, as listed4.8. Reacciones adversas · Trastornos del aparato reproductor y de la mama · Poco frecuentes The same text also says4.8. Reacciones adversas A table cell or list line is shown whole, as the text prints it. Some of them also name side effects that are not sexual. | Text for professionals Ficha técnicaPristiq 50 mg y 100 mg comprimidos de liberación prolongada, Pfizer, S.L. · Read in the regulator's own database: CIMAAlso on record: patients' leaflet, with such a sentence; related document, with such a sentence | Text revisedChecked |
| Brazil | Sexual side effects that continue after stopping5. ADVERTÊNCIAS E PRECAUÇÕES · Disfunção sexual Sexual side effects, as listed9. REAÇÕES ADVERSAS · Distúrbios psiquiátricos · Comum ≥1/100 a <1/10 Sexual side effects, as listed9. REAÇÕES ADVERSAS · Distúrbios psiquiátricos · Incomum ≥1/1000 a <1/100 Sexual side effects, as listed9. REAÇÕES ADVERSAS · Distúrbios do sistema reprodutivo e mamas · Comum ≥1/100 a <1/10 Sexual side effects, as listed9. REAÇÕES ADVERSAS · Distúrbios do sistema reprodutivo e mamas · Incomum ≥1/1000 a <1/100 The same text also says9. REAÇÕES ADVERSAS This is the holder's own copy. The regulator's database refused our requests (it blocks by country; we asked from Denmark). A table cell or list line is shown whole, as the text prints it. Some of them also name side effects that are not sexual. | Text for professionals PRISTIQ succinato de desvenlafaxina monoidratado: bula para o profissional de saúdePristiq comprimidos revestidos de liberação prolongada 50 mg e 100 mg, Pfizer Brasil Ltda. · Read on the holder's own site: Pfizer Brasil Ltda.Also on record: patients' leaflet, with such a sentence | Text approvedChecked |
| India | Sexual side effects, as listedUndesirable Effects Sexual side effects, as listedUndesirable Effects This text has no sentence about sexual side effects continuing after the medicine is stopped. This is the holder's own copy. This regulator publishes no database of such texts. The originator product's text could not be opened. This is the text of another product, the one named in this row. A table cell or list line is shown whole, as the text prints it. Some of them also name side effects that are not sexual. | Text for professionals D-VENLOR TabletsD-VENLOR film-coated extended-release tablets, Cipla Ltd. · Read on the holder's own site: Cipla (ciplamed.com) | Text revisedChecked |
Brand names
These are the brand names of desvenlafaxine we saw in the official lists, compendia and regulators' pages we opened on or after 20 October 2026. A country may have more.
- Pristiq
- United States, Canada, Spain, Brazil
- Faxilex
- Italy
- Exital
- Spain
- Afax
- Brazil
- Andes
- Brazil
- Aviv
- Brazil
- Deller
- Brazil
- Desdiff
- Brazil
- Desduo
- Brazil
- Desenvo
- Brazil
- Destyc
- Brazil
- Desve
- Brazil
- Desventag
- Brazil
- Elifore
- Brazil
- Imense
- Brazil
- Rytmise
- Brazil
- Vellana
- Brazil
- Vendexla
- Brazil
- Venlapress
- Brazil
- Vyxara
- Brazil
- Zodel
- Brazil
What is not known
- No reliable figure exists for how often PSSD happens. (source)
- One study of health records gives an estimate for men, counted through prescriptions for erection medicines. (source)
- It is not known how many people fully recover. (source)
- None of the product texts we read says how long the sexual dysfunction can last. (source)
Code and reporting
In a report to a medicines regulator, the term is Post-SSRI sexual dysfunction (MedDRA code 10086208). Where to report, country by country
Every row in this table was checked on or after . To quote this record, name SIDEfxHUB and give this page's address. All medicines and countries · The whole record as a file: JSON · CSV · How these texts are checked
You may reuse this record under CC BY 4.0 if you credit SIDEfxHUB and give this page's address. The licence covers our compilation, not the texts quoted in it, in the original or in our translation, and not the article above.
Milnacipran: what the official texts say, country by country
For the SNRI antidepressant milnacipran (Savella), the product information we read in France, that of a generic product, says that cases of sexual dysfunction have been reported whose symptoms continued after SSRIs or SNRIs were stopped. This is known as post-SSRI sexual dysfunction (PSSD). The EU medicines regulator set the wording of this warning in 2019 for ten medicines, milnacipran among them. In Australia, the product information for Joncia has a warning about reports of sexual dysfunction that lasted a long time after SSRIs or SNRIs were stopped. In the United States, Savella is a medicine for fibromyalgia, and its text for professionals has no such sentence.
This is a record of what each text says and of the date it prints. A text is quoted in its own words, or summarised where the row says so. It is not a comparison of countries. All medicines and countries
Milnacipran: the official texts, country by country (9 texts read)
| Country or region | What the text says | Document | Dates |
|---|---|---|---|
| United Kingdom | We found no product with this medicine on 20 October 2026. | Text for professionalsWhere we looked: www.gov.uk/government/publications/antidepressants-use-and-safety--2/selective-serotonin-reuptake-inhibitors-ssris-and-serotonin-and-noradrenaline-reuptake-inhibitors-snris-use-and-safety | Checked |
| European Union | Sexual side effects that continue after stopping3. Serotonin and noradrenaline reuptake inhibitors (SNRI); selective serotonin reuptake inhibitors (SSRI) – Persistent sexual dysfunction after drug withdrawal (EPITT no 19277) · Summary of product characteristics · 4.4. Special warnings and precautions for use · Sexual dysfunction Sexual side effects that continue after stopping3. Serotonin and noradrenaline reuptake inhibitors (SNRI); selective serotonin reuptake inhibitors (SSRI) – Persistent sexual dysfunction after drug withdrawal (EPITT no 19277) · Package leaflet · 2. What you need to know before you take [Invented name] · Warnings and precautions The wording is for ten medicines: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, desvenlafaxine, duloxetine, milnacipran and venlafaxine. This is wording for national product texts. There is no single EU product text for this medicine. | Document from the regulator New product information wording – Extracts from PRAC recommendations on signals. Adopted at the 13-16 May 2019 PRACRead on the regulator's site: European Medicines AgencyAlso on record: 1 more related document, with such a sentence | PublishedChecked |
| United States | Sexual side effects, as listed5 WARNINGS AND PRECAUTIONS · 5.11 Patients with a History of Dysuria Sexual side effects, as listed5 WARNINGS AND PRECAUTIONS · 5.12 Sexual Dysfunction The same text also says5 WARNINGS AND PRECAUTIONS · 5.12 Sexual Dysfunction Sexual side effects, as listed6 ADVERSE REACTIONS · 6.1 Clinical Trials Experience · Genitourinary Adverse Reactions in Males Sexual side effects, as listed6 ADVERSE REACTIONS · 6.2 Postmarketing Experience · Reproductive System and Breast Disorders The same text also says6 ADVERSE REACTIONS · 6.2 Postmarketing Experience This text has no sentence about sexual side effects continuing after the medicine is stopped. On 20 October 2026 we searched the labels in openFDA, the FDA's open database. A sentence about sexual dysfunction continuing after stopping stood on none of the 12 labels in that database that name milnacipran. A table cell or list line is shown whole, as the text prints it. Some of them also name side effects that are not sexual. | Text for professionals SAVELLA® (milnacipran HCl) tablets: Full Prescribing InformationSavella film-coated tablets 12.5 mg, 25 mg, 50 mg and 100 mg, and titration kit, Allergan, Inc. · Read in the government's medicines database: DailyMedAlso on record: patients' leaflet, with no such sentence | Text revisedChecked |
| Canada | We found no product with this medicine on 20 October 2026. | Text for professionalsWhere we looked: health-products.canada.ca/dpd-bdpp/ | Checked |
| Australia | Sexual side effects that continue after stoppingSection 4.4 · Sexual dysfunctionSection 4.4 of Australia's product information for Joncia has a warning headed sexual dysfunction. It says there are reports of sexual dysfunction that lasted a long time, with symptoms going on after SSRIs or SNRIs were stopped.Summarised, not quoted, because of the TGA's access terms.In this product's text since 2020, according to the text for professionals, 18 February 2020. The regulator's site asks readers to accept its terms before it shows this text. | Text for professionals AUSTRALIAN PRODUCT INFORMATION – JONCIA® (MILNACIPRAN HYDROCHLORIDE) HARD CAPSULEJONCIA, Pierre Fabre Australia Pty Limited · Read in the regulator's own database: TGA eBSAlso on record: patients' leaflet, with no such sentence | Text revisedChecked |
| New Zealand | We could not open this text on 20 October 2026: the site did not answer. This says nothing about what the text contains. | Text for professionalsWe tried: www.medsafe.govt.nz/DbSearch/ | Tried |
| Germany | Sexual side effects that continue after stoppingPRAC-Meldungen · Neufassung des Wortlauts der Produktinformationen – Auszüge aus den Empfehlungen des PRAC zu Signalen · Serotonin- und Noradrenalin-Wiederaufnahmehemmer (SNRI); selektive Serotonin-Wiederaufnahmehemmer (SSRI) – persistierende sexuelle Funktionsstörung nach Absetzen von Arzneimitteln (EPITT Nr. 19277) The wording is for ten medicines: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, desvenlafaxine, duloxetine, milnacipran and venlafaxine. | Document from the regulator Bulletin zur Arzneimittelsicherheit – Informationen aus BfArM und PEI, Ausgabe 2 | Juni 2019Read on the regulator's site: BfArMAlso on record: text for professionals, could not be opened | PublishedChecked |
| France | Sexual side effects that continue after stopping4.4. Mises en garde spéciales et précautions d'emploi · Dysfonction sexuelle Sexual side effects, as listed4.8. Effets indésirables · Affections psychiatriques · Peu fréquent (≥ 0,1 % à 1 %) Sexual side effects, as listed4.8. Effets indésirables · Affections des organes de reproduction et du sein · Fréquent (≥ 1 % à 10 %) The same text also says4.8. Effets indésirables The text itself prints no date of revision. The originator product is not in the list we read. This is another product from that list. A table cell or list line is shown whole, as the text prints it. Some of them also name side effects that are not sexual. | Text for professionals Résumé des Caractéristiques du Produit (RCP)MILNACIPRAN ARROW 25 mg, gélule, ARROW GENERIQUES · Read in the government's medicines database: Base de données publique des médicamentsAlso on record: patients' leaflet, with such a sentence | Updated by the regulatorChecked |
| Italy | We found no product with this medicine on 20 October 2026. | Text for professionalsWhere we looked: medicinali.aifa.gov.it/ | Checked |
| Spain | We found no product with this medicine on 20 October 2026. | Text for professionalsWhere we looked: cima.aemps.es/cima/publico/lista.html | Checked |
| Brazil | Anvisa's register lists milnacipran only under registrations marked inactive: two for Ixel and one under the substance's name. None is marked active. We found no product with this medicine on 20 October 2026. | Text for professionalsWhere we looked: dados.anvisa.gov.br/dados/DADOS_ABERTOS_MEDICAMENTOS.csv | Checked |
| India | We could not open this text on 20 October 2026: this regulator publishes no database of such texts. This says nothing about what the text contains. | Text for professionalsWe tried: cdsco.gov.in/opencms/opencms/en/Notifications/Prescribing-Information/ | Tried |
Brand names
These are the brand names of milnacipran we saw in the official lists, compendia and regulators' pages we opened on or after 20 October 2026. A country may have more.
- Savella
- United States
What is not known
- No reliable figure exists for how often PSSD happens. (source)
- One study of health records gives an estimate for men, counted through prescriptions for erection medicines. (source)
- It is not known how many people fully recover. (source)
- None of the product texts we read says how long the sexual dysfunction can last. (source)
Code and reporting
In a report to a medicines regulator, the term is Post-SSRI sexual dysfunction (MedDRA code 10086208). Where to report, country by country
Every row in this table was checked on or after . To quote this record, name SIDEfxHUB and give this page's address. All medicines and countries · The whole record as a file: JSON · CSV · How these texts are checked
You may reuse this record under CC BY 4.0 if you credit SIDEfxHUB and give this page's address. The licence covers our compilation, not the texts quoted in it, in the original or in our translation, and not the article above.